Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer
K. Blackwell(GlaxoSmithKline (United States)), M. S. Berger(Duke University), Mark D. Pegram(Stanford University), X. Lin(GlaxoSmithKline (United States)), Harold J. Burstein(Dana-Farber Cancer Institute), Neil L. Spector(Duke University), Vanessa Salazar(GlaxoSmithKline (United States)), Steven H. Stein(GlaxoSmithKline (United States)), A. M. Storniolo(University School), Janet Maleski(GlaxoSmithKline (United States))
Cited by 66
Related Papers
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830